Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Despite widespread use of statins to reduce low-density lipoprotein cholesterol (LDL-C) and associated atherosclerotic cardiovascular risk, many patients do not achieve sufficient LDL-C lowering due to muscle-related side effects, indicating novel treatment strategies are required. Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK) activity in rodents. However, its mechanism for LDL-C lowering, efficacy in models of atherosclerosis and relevance in humans are unknown. Here we show that ETC-1002 is a prodrug that requires activation by very long-chain acyl-CoA synthetase-1 (ACSVL1) to modulate both targets, and that inhibition of ACL leads to LDL receptor upregulation, decreased LDL-C and attenuation of atherosclerosis, independently of AMPK. Furthermore, we demonstrate that the absence of ACSVL1 in skeletal muscle provides a mechanistic basis for ETC-1002 to potentially avoid the myotoxicity associated with statin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 ETC-1002-CoA inhibits ACL and mediates β1-selective AMPK activation. Recombinant human ACL was incubated in the presence of the indicated concentrations of ETC-1002-CoA (a–c) or ETC-1002 (d), and (a) coenzyme A (CoA), (b) citrate or (c) ATP. Conversion of [14C]-citrate to [14C]-acetyl-CoA was measured in counts per minute (CPM). Recombinant human (e) AMPKα1β1γ1 and (f) AMPKα1β2γ1 complexes were incubated in the presence of the indicated concentrations of ETC-1002, ETC-1002-CoA, AMP or A-769622. (g) Structure of ETC-1002 and the biochemical reaction that generates ETC-1002-CoA acyl-CoA synthetase (ACS). ETC-1002-CoA/CoASH enzyme ACL kinetic analyses are single measures, and representative results from n=3 independent experiments shown; AMPK activity was determined by time-resolved fluorescence resonance energy transfer expressed as mean±s.e.m. of triplicate measures. (a) Ki calculated by Michaelis–Menten kinetic analysis.](https://figures.cochat.ai/paper-figures/02df10a0267b44eda297dc9dcee13726/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-1.jpg)
![Figure 2 Differentiation of ETC-1002 from the myotoxic effects of statins. [14C]-ETC-1002 (10 μM) conversion to [14C]-ETC-1002-CoA in human liver microsomes was determined in the presence of 30 μM unlabelled (a) monocarboxylic and (b) dicarboxylic saturated competitive fatty acid substrates. RH7777 cells were treated with negative control (Control) or Slc27a2 (ACSVL1) siRNA; n=6, for 48 h, and (c) ACSVL1 expression determined by western blot, and [14C]-ETC-1002-CoA synthesis determined; n=3. (d) Both control and Slc27a2 siRNA-treated RH7777 cells were treated with vehicle, ETC-1002 (30 μM) or atorvastatin (0.5 μM), and de novo cholesterol synthesis measured over 4 h; n=6 transfections. (e) Relative ACSVL1 expression in microsomes prepared from human liver, kidney and skeletal muscle (SkM). (f) ETC-1002-CoA synthetase activity in microsomes prepared from human liver and skeletal muscle; palmitate (10 μM) used as a positive control for skeletal muscle microsome viability. (g) ACSVL1 expression was measured in primary human hepatocytes and primary human skeletal muscle (SkM) cells by western blotting and expressed relative to β-actin. (h) Primary human myotubes were treated with vehicle (Veh.), simvastatin 10 μM (Simva), atorvastatin 10 μM (Atorva) or ETC-1002 100 μM in the presence of [14C]-glucose for 12 h, and incorporation into non-saponifiable lipids determined; or treated with 0.1–100 μM simvastatin, atorvastatin or ETC-1002 for 48 h and (i) cytotoxicity was measure by GF-AFC/bis-AAF-R110 cleavage, and (j) Caspase 3,7 activity (DEVD cleavage) determined. Data for myotube cytotoxicity assays are expressed as mean±s.e.m., n=2 performed in triplicate. Data for liver (n=50 donors pooled) and kidney (n=50 donors pooled) microsome preparations are representative of two independent experiments performed in duplicate, and expressed as mean±s.d. Data for human skeletal muscle microsomes (n=4 pooled donors) are the mean±s.e.m. of two independent experiments performed in triplicate. Multiple comparisons were made using an one-way ANOVA, Bonferroni's multiple comparisons test; *P<0.05.](https://figures.cochat.ai/paper-figures/aa53cfde988849fa938e4aa3379a9671/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-2.jpg)


![Figure 5 ACL suppression increases LDLR. (a) Primary human hepatocytes were treated with vehicle or ETC-1002 (100 μM) for 18 h in the presence of [3H]-H2O or pretreated with the indicated concentrations of ETC-1002 for 1 h, following a 3 h [14C]-acetate pulse. Counts incorporated into the non-saponifiable (sterols), and saponifiable (fatty acids) lipid fractions were determined and expressed as % vehicle. (b) Primary human hepatocytes were treated with vehicle, atorvastatin (0.5 μM) or ETC-1002 (100 μM) for 36 h and total intracellular cholesterol concentrations were determined in cell lysates. (c) Media was assayed for apoB by enzyme-linked immunosorbent assay. (d) PHHs were treated with ETC-1002 for the indicated time points and the apoB concentrations were measured in the media. (e) PHH were pre-labelled overnight with [14C]-oleate and the effects of ETC-1002 treatment on oleate-derived counts in the media determined at the indicated time points. PHH hepatocytes were treated with ETC-1002 and atorvastatin, and (f) mRNA levels for HMGR, SREBF2, PCSK9 and LDLR were determined by reverse transcription–quantitative PCR or (g) LDL receptor activity determined; A-769662 (10 μM). (h) RH7777 cells were treated with the indicated concentrations of ETC-1002 or atorvastatin (0.5 μM), and [14C]-lactate incorporation into cholesterol (Chol), cholesteryl esters (CE) and triglycerides determined. (i) LDLR-mediated DiI–LDL uptake in response to the indicated concentrations of ETC-1002±atorvastatin (0.5 μM). RH7777 cells were subjected to negative control (NC) or Acly siRNA-mediated gene silencing (n=3) and analysed for (j) ACL LDLR protein levels, or (k) LDLR-mediated DiI–LDL uptake. Data for PHH are expressed as mean±s.e.m. of n=2 donors performed in triplicate (a–c,f,g; except A-769662 treatment was 1 donor) or representative of two independent experiments showing similar results (d,e). (h) IC50 and (i) EC50 determinations were made using nonlinear curve fit model. Multiple comparisons were made using (a,j,k) unpaired Student's t-test or (b,c,f,g) an one-way ANOVA, Bonferroni's multiple comparisons test; *P<0.05.](https://figures.cochat.ai/paper-figures/bdd7bd8103b34bfd9b8c72b35fad6960/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bempedoic acid is a pro-drug that reduces cholesterol synthesis by inhibiting adenosine triphosphate (ATP) citrate lyase, with very limited musculoskeletal-related side effects.280”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [280]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081 · cited 1×
“Triacsin C is a potent inhibitor of ACSL1 and 4, and a weak inhibitor of ACSVL1 (refs 43–47).”
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834 · cited 1×
“Upregulation of the LDL receptor results in a new homeostatic state, where more cellular cholesterol is derived from blood LDL particles, thus reducing blood LDL-C 51–53 .”
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Mihaylova, M. M., & Shaw, R. J. (2011) · Nature Cell Biology · doi:10.1038/ncb2329 · Cited by 2,923
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Cited by
Items 301–400 of 499
Bempedoic Acid and Statins in Lipid-Lowering Strategy: Which Came First, the Egg or the Chicken?
Natale, F., Molinari, R., Franzese, R., Mollo, N., & Cimmino, G. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3020024 · Cited by 5
“This results in a reduction in the endogenous synthesis of cholesterol in the liver [18].”
Background2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid
Kim, H., Cha, J., & Lee, S. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.2.135 · Cited by 7
“32,36,37 Approximately 70% of BA and its active metabolite, bempedoil-CoA, are cleared by the renal system, while the liver eliminates the remaining 30%.”
Zhang, Q., Pan, Y., Ma, X., Yang, H., Chang, J., Hong, L., Yan, H., & Zhang, S. H. (2021) · PubMed Central · doi:10.22074/cellj.2021.7033 · Cited by 5
“Our data also show that Aldo is not significantly correlative to LDL-C (Fig.1F).”
BackgroundInfluentialWagner, M., Leefmann, J., Künzel, S. R., Schmidt, M. M., & El‐Armouche, A. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1136-4356 · Cited by 4
“Die ebenfalls beschriebene Aktivierung der AMP-aktivierten Proteinkinase (AMPK) scheint nicht zur LDL-C-senkenden Wirkung beizutragen [8].”
InfluentialKaur, K. K. (2022) · Advances in Obesity Weight Management & Control · doi:10.15406/aowmc.2022.12.00367 · Cited by 6
Bempedoic acid: what prospective uses?
Jacomelli, I., Monzo, L., Panattoni, G., Lanzillo, C., Rebecchi, M., & Calò, L. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad012 · Cited by 4
“Bempedoic acid is a prodrug that need to be actived in bempedoyl CoA, by the enzyme very long-chain acyl-CoA synthease-1 (ACSVL1).(5) It is the first orally administered drug in the class of the ACLY inhibitors.”
BackgroundYaseen, M. S., & Ali, N. A. K. M. (2022) · Cellular and Molecular Biology · doi:10.14715/cmb/2022.68.10.15 · Cited by 7
“Both drugs showed similar profiles in blood pressure and heart rate measurements. acid is a prodrug, given orally once daily, which must be activated by the very long-chain acyl-CoA synthetase 1 in the liver, which is lacking in the majority of peripheral tissues (9).”
BackgroundSayed, A., & Brophy, J. M. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132074 · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Methods to Evaluate AMPK Regulation of Macrophage Cholesterol Homeostasis
LeBlond, N. D., & Fullerton, M. D. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7598-3_30 · Cited by 6
Michos, E. D., & Ferdinand, K. C. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.9 · Cited by 8
Rovera, C., Zoppo, A. D., Petralli, G., Moriconi, D., Rossi, C., Distaso, M., Brunetto, M. R., Ferrannini, E., Raggi, F., & Solini, A. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104373 · Cited by 3
Pavanello, C., Cincotto, G., Mombelli, G., Castiglione, S., Santolamazza, C., Calabresi, L., Sirtori, C., & Alberti, A. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.09.033 · Cited by 4
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima, A., Serruys, P. W. J. C., Garg, S., McEvoy, J. W., Wood, D., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., et al. (2026) · EuroIntervention · doi:10.4244/eij-d-25-00598 · Cited by 4
Targeting Fatty Acids in Liver Cancer: Molecular Insights and Drug Approaches
Cigliano, A., Pischedda, D., Pandino, C., Galleri, G., & Calvisi, D. F. (2026) · Biomolecules · doi:10.3390/biom16020329 · Cited by 3
“Moreover, it increases AMPK activity, affecting the phosphorylation of ACC and HMG-CoA reductase [170,171].”
Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes Trial
Naderi, S., Brennan, D. M., Li, N., Lincoff, A. M., Nicholls, S. J., Nissen, S. E., Plutzky, J., Powell, H. A., Robinson, P. L., & Cho, L. (2026) · Clinical Cardiology · doi:10.1002/clc.70288 · Cited by 3
Targeting ATP-Citrate Lyase Across Cardiometabolic and Oncologic Disease.
Macchi, C., Pedretti, S., Ghisletti, S., Corsini, A., Mitro, N., Sirtori, C., & Ruscica, M. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108348 · Cited by 3
Shen, F., Chu, C., Chen, J., Kuo, C., Hsu, C., Lin, C., Sheen, Y., Su, S., Tien, K., Lu, C., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14222 · Cited by 4
“Bempedoic acid is a liver-speci fi c prodrug activated primarily in the liver, reducing muscle-related side effects 56 .”
BackgroundOgunniyi, K. E., Aghasili, C. C., Akinmoju, O. D., Olaiya, V. O., Abib, O. M., Odueke, A., Popoola, H. A., Onyenokwe, V., Onaolapo, D., Usman, A.-A. M., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00762-9 · Cited by 3
Further options for treating lipids in people with diabetes: targeting LDL ‐cholesterol and beyond
Wierzbicki, A. S. (2018) · Diabetic Medicine · doi:10.1111/dme.13667 · Cited by 5
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 4
Gergely, T. G., Brenner, G. B., Nagy, R. N., Sayour, N. V., Makkos, A., Kovácsházi, C., Tian, H., Schulz, R., Giricz, Z., Görbe, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021585 · Cited by 4
“It has been shown that bempedoic acid is a prodrug activated in the liver, but not in the skeletal muscle [12]; thus, it potentially leads to fewer muscle-related adverse effects compared to statins.”
BackgroundLuca, L. D., Riccio, C., Navazio, A., Valente, S., Cipriani, M., Corda, M., Nardo, A. D., Francese, G. M., Napoletano, C., Tizzani, E., et al. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad100 · Cited by 3
“37 Bempedoic acid acts by inhibiting ATP citrate lyase, a cytosolic enzyme located within the enzymatic cascade leading to cholesterol synthesis ( Figure 1 ).”
BackgroundPark, J. K., Balarbar, N., & Agarwala, A. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01911-9 · Cited by 4
Carpio-Tenorio, C. D., Llerena-Velastegui, J., Villacis‐Lopez, C., Placencia‐Silva, M., Santander-Fuentes, C., Benitez-Acosta, K., Sanahuja-Montiel, C., Dominguez-Gavilanes, D., Carrasco-Perez, P., & Calderon-Lopez, C. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102191 · Cited by 3
Kong, X., He, G., Quan, X., Tan, Z., Yan, F., & Chen, X.-H. (2024) · Medicine · doi:10.1097/md.0000000000037637 · Cited by 4
“[18] Studies have shown that bempedoic acid reduces LDL-C levels by ~30% and by approximately 50% in combination with ezetimibe.”
BackgroundLu, J., Li, G. H., Hu, J., & Wang, Z. (2025) · Communications Biology · doi:10.1038/s42003-025-07860-z · Cited by 4
Bempedoinsäure – Wirkmechanismus und klinische Studien
Katzmann, J. L., & Laufs, U. (2020) · Aktuelle Kardiologie · doi:10.1055/a-1142-7957 · Cited by 3
“Dies führt zu einer verminderten Lipidmodifikation (Isoprenylierung) und verminderten Produktion von Stoffwechselprodukten, die zur Aufrechterhaltung der Integrität der Muskelzelle notwendig sind, und stellt ein mögliches pathophysiologisches Korrelat für statinassoziierte Muskelschmerzen dar [3].”
BackgroundInfluentialBempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia
Schimmenti, C., Sucato, V., Manzone, E., Cancellieri, G., Mortillaro, F., Novo, G., Galassi, A. R., & Venturella, F. (2020) · Coronary Artery Disease · doi:10.1097/mca.0000000000000976 · Cited by 3
Gupta, Y. A., Maciorowski, D., Mathur, R., Pearce, C. M., Ilc, D. J., Husein, H., Bharti, A., Becker, D. P., Rathi, B., Bradfute, S. B., et al. (2020) · Preprints.org · doi:10.20944/preprints202005.0199.v1 · Cited by 6
Alternate models of acute dyslipidemia reveal divergent pathways upon atherosclerosis initiationPreprint
Hellberg, S., Shavva, V. S., Metso, J., Chen, G., Li, Q., Manfé, V., Olofsson, P. S., Jauhiainen, M., Binder, C. J., & Malin, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.02.279596 · Cited by 3
Yenilmez, B., Kelly, M., Zhang, G., Wetoska, N., Ilkayeva, O., Min, K., Rowland, L. A., DiMarzio, C., He, W., Raymond, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.21.485183 · Cited by 3
“Bempedoic acid is converted to its bioactive form by very long chain acyl-CoA synthase (ACSVL1), which is purported to be liver-specific (38, 70-74).”
BackgroundKlose, G., Gouni‐Berthold, I., & März, W. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01524-y · Cited by 2
Current Perspectives of Diabetic Dyslipidemia and Treatment Modalities
Akkuş, G. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673336501241001093417 · Cited by 4
Bempedoic Acid: A Review in Cardiovascular Risk Reduction in Statin-Intolerant Patients
McGuigan, A., & Blair, H. A. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00714-9 · Cited by 4
“Bempedoic acid is an inhibitor of the ACL enzyme involved in the cholesterol biosynthesis pathway [9, 10].”
InfluentialJe, I., Park, J.-T., Lee, H. J., Im, A., Lee, J., & Kim, K.-Y. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128387531250713164724 · Cited by 2
Wang, Y., Wang, P., Xu, F., Zhou, H., Xie, X., Hou, T., Luo, F., Sun, Y., Liu, Y., Wang, J., et al. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.106874 · Cited by 2
Inhibition of ATP citrate lyase does not affect muscle mitochondrial activity in apoE-/- mice
Macchi, C., Fichtner, I., Mohamed, T., Franchi, E., Rizzuto, A. S., Pavanello, C., Gindlhuber, J., Nerini, S., Sirtori, C. R., Osto, E., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118726 · Cited by 2
Masuda, D., Kajinami, K., Sakayoshi, N., Yokota, D., Nagamine, M., Isogai, Y., & Yamashita, S. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65947 · Cited by 3
“This tissue-specific activation may help to reduce the risk of muscle-related adverse effects (AEs) commonly seen with statin therapy 8) .”
Xiao, Q., Wang, M., Wang, S., Wang, L., & Ding, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07647-0 · Cited by 3
“…: ~21.6% decrease [52] CLEAR Outcomes: reduced composite CV events in statin-intoler-ant pts [52] Hyperuricemia/gout [53] Increase LDLR expression [54] Accelerate the clearance of LDL-C [51] Inclisiran (siRNA, GalNAc) RNAi to suppress hepatic PCSK9 synthesis [55] LDL-C : ~50% decrease (twice…”
InfluentialBouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Macrophage-associated kinase signaling in atherosclerosis – a systematic review
Müller, J. S., & van der Vorst, E. P. C. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02829-9 · Cited by 2
Alkayed, H. A., Rajesh, R., Shaikh, A., Martins, R., & Alrabadi, B. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.04.015 · Cited by 3
Are we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
PCSK9 inhibitors: an updated patent review 2024–2025
Fassi, E. M. A., Albani, M., d’Adduzio, L., Milano, E. G., Lammi, C., & Grazioso, G. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2674748 · Cited by 2
“Bempedoic acid acts by cutting off the supply via ATP-citrate lyase shutdown [10].”
Li, X., Bai, L., Zhang, Y., Wang, Y., Shi, Y., & Liu, H. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119549 · Cited by 2
Hypercholesterinämie und kardiovaskuläres Risiko
Sinning, D., & Landmesser, U. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1932-6448 · Cited by 2
Nisar, S., Sohail, S., Fatima, S., Akhtar, M. T., Ahmad, M., Hanif, M. W., Khan, M., Mehmoodi, A., & Malik, J. (2024) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1313 · Cited by 3
“21 ACLY regulates the fl ow of extra-mitochondrial citrate, which is essential for the synthesis of lipids.”
BackgroundHigh expression of CASP1 induces atherosclerosis
Li, Y., Du, L., Meng, L., Lv, C., & Tian, X. (2024) · Medicine · doi:10.1097/md.0000000000037616 · Cited by 2
“[15–18] The stability of plaque plays an important role in the progression and complications of atherosclerosis.”
BackgroundEfficacy and Safety of Bempedoic Acid as a Treatment Option for Hyperlipidemia: A Systematic Review
Sharif, M. H., Orakzai, A. A., Khaleeque, M., Raza, S. S., Khan, O. S., Jan, M. H., Ahmed, A., & Arsalan, M. (2024) · Advances in Clinical Medical Research and Healthcare Delivery · doi:10.53785/2769-2779.1198 · Cited by 1
Goyal, A., Shah, S., Dahal, K., Changez, M. I. K., Tariq, M. D., Zuhair, V., Shamim, U., Abbasi, H. Q., Shrestha, A. B., Sah, R., et al. (2024) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000302 · Cited by 3
“BA can be administered either as a standalone treatment or as an adjunctive therapy alongside statins combined with and without ezetimibe [6,7].”
Effects of ACLY Inhibition on Body Weight Distribution: A Drug Target Mendelian Randomization Study
Gill, D., Dib, M.-J., Gill, R., Bornstein, S., Burgess, S., & Birkenfeld, A. (2024) · Genes · doi:10.3390/genes15081059 · Cited by 2
“In fact, clinical trial data have shown that bempedoic acid, an ACLY inhibitor, reduces low-density lipoprotein cholesterol (LDL-c) levels and subsequently lowers cardiovascular disease (CVD) risk [12,13].”
BackgroundMohamed Anasdeen, S., Shahinaz, S., & Vijayakumar, T. M. (2024) · Cureus · doi:10.7759/cureus.67151 · Cited by 5
Integrated review of cardiometabolic biomarkers and dietary nutrients
Vermaa, R., Bisen, P. S., & Bulló, M. (2024) · Journal of Food Bioactives · doi:10.26599/jfb.2024.95027386 · Cited by 2
Zhao, Y., Zhang, A., Feng, S., Liu, T., Ning, J., Zhang, Y., Cheng, J. Q., Zhang, Q., & Wang, C. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.136906 · Cited by 2
Benucci, M., Terenzi, R., Gobbi, F. L., Cassarà, E. A. M., Picchioni, T., Russo, E., Lari, B., Manfredi, M., & Infantino, M. G. (2025) · Antibodies · doi:10.3390/antib14030063 · Cited by 2
“Moreover, among the genetic risk factors, the MHC class II allele HLA-DRB111:01 has been strongly associated with a predisposition to anti-HMGCR-positive IMNM [11,12].”
Nuevos tratamientos en la dislipemia
de Isla, L. P., & Valdivielso, P. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.003 · Cited by 5
Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease
Noh, S., Mai, K., Shaver, M., Yong, S., MOSTAGHIMI, M., Oh, G., & Radwan, M. M. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.12.011 · Cited by 3
Clinical strategies for reducing cholesterol levels
Lardinois, C. K., & Karr, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00027-4 · Cited by 2
The Pathogenetic Basis of the Action of Bempedoic Acid
Petrosyan, A. S., Rud', R. S., Polyakov, P. P., Каде, А. Х., & Zanin, S. A. (2023) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2022-12-11 · Cited by 2
Pathy, K. (2019) · Surgery & Case Studies Open Access Journal · doi:10.32474/scsoaj.2019.03.000154 · Cited by 2
The mega-importance of de novo lipogenesis in platelet production
Nazy, I., Arnold, D. M., & Steinberg, G. R. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00282-7 · Cited by 2
Self-citationWorking towards full eradication of lipid-driven cardiovascular risk?
Nurmohamed, N. S., & Stroes, E. S. G. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01600-8 · Cited by 2
Synthesis of Bempedoic Acid through Electrochemical Decarboxylation of Dialkylated Malonic Acid
Tian, L., Wang, Y., Xu, Z., & Zheng, Y. (2021) · Synthesis · doi:10.1055/a-1482-9822 · Cited by 3
Novel LDL-cholesterol lowering therapies: A step forward a personalized medicine
Averna, M. R., & Cefalu, A. B. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.04.026 · Cited by 1
Serhiyenko, V. A., & Serhiyenko, A. A. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.3.2023.1275 · Cited by 1
Lipids, Lipoproteins, and Cardiovascular Outcomes
Sakers, A. P., Mszar, R., & Soffer, D. E. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_9 · Cited by 1
Efficacy and Safety of Bempedoic Acid in Lipid Disorder Therapy: A Review of Clinical Trials
Dąbrowska, P., Żuber, M., & Dacka, M. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.208 · Cited by 1
“…objawy ze strony układu mięśniowego, takie jak ból mięśni i skurcze, które mogą być podobne do tych obserwowanych przy stosowaniu statyn, jednakże, jak wcześniej wspomniano , w przeciwieństwie do statyn, kwas bempediowy działa specyficznie w wątrobie, co zmniejsza ryzyko m iopatii [16].”
Multifaceted analysis of bempedoic acid binding to subdomain IIA of human serum albumin
Abubakar, M., Hidayat, A. F. A., Mohamad, S. B., Halim, A. A. A., Khanna, K., Rajagopal, M. S., & Tayyab, S. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140435 · Cited by 1
Chaudhari, M. V., Chaudhari, U., Sahu, J. K., Srivastava, S. K., Sharma, S., & Sahu, A. (2024) · Current Analytical Chemistry · doi:10.2174/0115734110335673241119051406 · Cited by 1
Discovery of Alkyl Conjugated Diene Diacids as Novel ACLY Inhibitors
Cheng, T., Song, G., Cheng, L., Wang, F., Sun, X., Xie, Z., Zhang, M., Zhang, Y., Li, J., & Nan, F. (2024) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc202405036 · Cited by 1
The effect of bempedoic acid on histopathologic changes associated with natural aging in rat lungs
Barış, S. A., Baris, O., Kaya, H., Guliyev, E. K., Olsen, C. A., Vural, Ç., Boyacı, H., & Başyiğit, İ. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03608-x · Cited by 1
“Hepatic gene expression analyses indicate that it suppresses the expression of inflammatory genes involved in lipid metabolism and significantly upregulates genes related to fatty acid oxidation [5, 6].”
Ali, A., Bhimani, S., Karmani, V. K., Dhillon, R. A., Saeed, S., Amir, A., Patel, P. S., Asif, A., Baig, U. A., Shamoon, S., et al. (2025) · Qatar medical journal · doi:10.5339/qmj.2025.51 · Cited by 1
“14,15 The recent CLEAR Outcomes trial (Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase-Inhibiting Regimen) evaluated the use of bempedoic acid in high-risk primary and secondary prevention patients who could not or would not take statin therapy due to intolerance.”
Abdullah, M., Khalid, N., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001111 · Cited by 1
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101725 · Cited by 3
Electrochemical Decarboxylative Hydroxylation for the Sustainable Synthesis of Bempedoic Acid
Ronco, P., Simi, A., Lunghi, E., Negra, F. D., Trucchi, B., Verzini, M., & Zanoni, G. (2026) · ChemElectroChem · doi:10.1002/celc.70173 · Cited by 1
Liu, X., Jia, L., Li, L., Huang, J., Hou, M., Li, Z., Yao, D., Yang, Y., Wang, J., & Dai, L. (2026) · Research · doi:10.34133/research.1272 · Cited by 1
Emerging roles of ATP citrate lyase in kidney diseases: from pathogenic driver to therapeutic target
Wei, M., Tao, M., Tan, H., Jin, Z., Yang, Y., Xiao, Z., Li, G., & Chen, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2652826 · Cited by 1
“…in hepatocytes and absent in skeletal muscle and intestinal tissue, a property that may help avoid myopathic side effects associated with statins [112]. the active metabolite acts as a potent, high-affinity, and concentration-dependent inhibitor of aCLY, with a reported half-maximal inhibitory…”
Oliver, M. A., Davis, X. D., & Bohannon, J. K. (2026) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiag047 · Cited by 1
“Statins, colchicine, and bempedoic acid interrupt the mevalonate-NLRP3 axis that sustains Western-diet-driven cardiac reprogramming 103,127–129 , 130 ; Emerging delivery platforms now make true tissue specificity feasible.”
Bempedoic acid and increased serum uric acid levels: a matter of concern?
Bonanni, L., Biolo, M., Marodin, G., Portinari, C., Simioni, P., & Ferri, N. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104755 · Cited by 1
Federici, M., Buzzetti, R., Candido, R., Cosmo, S. D. D., Pirillo, A., Russo, G., Sesti, G., & Avogaro, A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03185-1 · Cited by 1
“As bempedoic acid is activated only in the liver and not in skeletal muscle, it is associated with a low risk of muscle adverse effects [35], a clinically relevant advantage in people with diabetes, who commonly report statin-associated muscle symptoms [78].”
Ciaula, A. D., Khalil, M., Garruti, G., & Portincasa, P. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101056 · Cited by 2
“An additional mechanism involves the enhanced he-patic LDL uptake through increased LDL receptor expression (4).”
Hsieh, I.-C., Chen, D., Chu, C., Chang, Y., Tzeng, B., Huang, T., Lin, H., Chuang, W., Huang, C., Yeh, J., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049917 · Cited by 3
“6 The statin reductase pathway has been associated with reduced endogenous ubiquinone (co-enzyme Q10) production, 32 which may contribute to statin-associated myalgia.”
Chapman, M. J., Thérond, P., & Meikle, P. J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109050 · Cited by 1
Familial Hypercholesterolemia: Improving Outcomes with Newer Agents
Ray, S., & Sarkar, B. (2020) · American Journal of Internal Medicine · doi:10.11648/j.ajim.20200806.17 · Cited by 1
“The inhibition of ACL, a key enzyme in intracellular cholesterol biosynthesis, depletes intracellular cholesterol, which upregulates the LDLR and increases LDL-C clearance [19].”
BackgroundAbordagens terapêuticas nas dislipidemias - com ênfase na ldl-c (aterogênica)
Guerra, T. D. R. B., Soares, A. D. C. L., Salviano, B. M., Palermo, M. V. A., Scofano, B. D. S., Netto, M. F. G., Nunes, B. E. M., & Tavares, A. P. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n2-288 · Cited by 2
Modern prospects of targeted hypolipidemic therapy
Kuchmin, A. N., Борисович, Н. М., Grachev, A. M., & Смирнова, Е. В. (2023) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma321350 · Cited by 1
Lipidmanagement zur Reduktion des kardiovaskulären Risikos bei Typ-2-Diabetes
Brandts, J. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01094-5 · Cited by 1
“Laut in-vivo-Studien jedoch ist der primäre Weg, der zur Reduktion von LDL-C und Atherosklerosebeiträgt,dieHemmungder ACL [14].”
BackgroundConquering cholesterol: a report from the front lines
Libby, P., Pinkosky, S. L., & Nissen, S. E. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad152 · Cited by 1
Self-citationFatty liver disease: Functional foods offer natural remedies
Zhao, M., Yi, Z., Zhang, B., Chen, S., Zhuang, X., Yin, H., & Zhao, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91747-6.00001-9 · Cited by 2
DESAFIOS FARMACOTÉCNICOS NA PRODUÇÃO DE EMULSÕES CREMOSAS À BASE DE EXTRATO SECO DE CÚRCUMA
dos Santos, P. L., de Morais, K. R. S., & Tescarollo, I. L. (2024) · doi:10.22533/at.ed.5122405042 · Cited by 1
CTRP9: An Anti-Atherosclerotic Factor in ApoE Knockout Mice through Oxidative Stress Inhibition
Guan, H., Xu, H., Yan, B., Xiang, A., Chen, X., Yu, Q., & Xu, L. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2909339 · Cited by 1
Sallam, M., Hassan, H., Connolly, D. L., & Rahman, M. S. (2024) · European Cardiology Review · doi:10.15420/ecr.2024.06 · Cited by 2
Sciahbasi, A., Russo, P., Zuccanti, M., Chiorazzo, L., Castelli, F., & Granatelli, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237420 · Cited by 1
Defining the role of bempedoic acid in lowering low-density lipoprotein cholesterol
Korzh, O. (2020) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2020.101217 · Cited by 2
“treatment reduced TG and LDL cholesterol levels in both genotype mice, while plasma amyloid A serum amyloid A (SAA) levels also decreased significantly (Pinkosky et al., 2016).”
BackgroundInfluentialLeBlond, N. D., Ghorbani, P., O’Dwyer, C., Ambursley, N., Nunes, J. R. C., Smith, T. K. T., Trzaskalski, N. A., Mulvihill, E. E., Viollet, B., Foretz, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.15.204487 · Cited by 1
Atherosclerosis: Cholesterol Management
Edmondson, S. D., Burnett, D. A., & Davis, H. R. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc185.pub2 · Cited by 1
“The compound itself is a prodrug that gets converted to bempedoic acid-CoA in vivo and it is this active drug that inhibits ACL in the liver [212].”
BackgroundFuture Energy Supply, Simulations with Limited Resources
Benichou, L. (2011) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Carvalho, G., Repolês, B. M., Nguyen, T., Forslund, J. M. E., Ranjbarian, F., Mendes, I. C., Falabella, M., Doimo, M., Wanrooij, S., Pitceathly, R. D. S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.14.584413 · Cited by 1
The highs and lows of cardiovascular disease prevention
Stock, J. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.005
Metadata
- Authors
- Pinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., Steinberg, G. R., & Lalwani, N. D.
- Affiliations
- Esperion Therapeutics (United States) (US)
- McMaster University (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- Corresponding author
- Pinkosky, Stephen L.
- Steinberg, Gregory R.
- Venue
- Nature Communications
- Published
- 2016-11-28
- Volume
- 7
- Issue
- 1
- Pages
- 13457-13457
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5133702
- OpenAlex
- W2558991743
- Cited by
- 498
- References
- 73
- Citations by year
- 2026: 63 · 2025: 50 · 2024: 76 · 2023: 79 · 2022: 55 · 2021: 67 · 2020: 50 · 2019: 24 · 2018: 21 · 2017: 10 · 2016: 1
- FWCI
- 21.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- Amgen
- Heart and Stroke Foundation of Canada
- McMaster University
- Esperion Therapeutics
- Amgen Canada
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- bempedoic acid, ATP citrate lyase, LDL cholesterol lowering, atherosclerosis, prodrug activation, LDL receptor upregulation, AMPK, hypercholesterolemia, skeletal muscle
- MeSH terms
- Adenylate Kinase, Animals, ATP Citrate (pro-S)-Lyase, Dicarboxylic Acids, Enzyme Activation, Enzyme Inhibitors, Fatty Acids, Humans, Cholesterol, LDL, Liver, Mice, Inbred C57BL, Models, Biological, Organ Specificity, Receptors, LDL, Up-Regulation, Mice, Knockout, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hepatocytes, Atherosclerosis, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.